Shilpa medicare Limited has announced its earnings conference call to discuss the financial results for the third quarter of FY26. The pharmaceutical company will host the call on February 6, 2026, providing investors and analysts an opportunity to review its performance for the quarter ended December 31, 2025.

Conference Call Schedule

The earnings call has been scheduled with comprehensive access arrangements for domestic and international participants. The company has made the announcement pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

International Access Numbers

The company has provided toll-free access numbers for international participants across key markets:

Participants are requested to dial-in 10 minutes before the scheduled time. The company has also provided a DiamondPass™ link for no-wait-time access to the conference call.

Company Overview

Shilpa Medicare Limited operates as an integrated pharmaceutical group with diversified business interests. The company focuses on niche Oncology and Non-oncology APIs, Peptides, Polymers, and differentiated finished dosage formulations including orally dispersible films and transdermal patches. Additionally, the company maintains a carefully crafted biological portfolio.

The pharmaceutical company provides comprehensive CDMO services to global pharmaceutical companies across all its business segments. This capability is supported by strong R&D and manufacturing infrastructure, including four R&D units and seven manufacturing facilities.

Regulatory Compliance

The earnings call announcement has been made available on the company's investor relations website at www.vbshilpa.com/investor-presentation.php . Company Secretary and Compliance Officer Ritu Tiwary signed the regulatory filing dated January 30, 2026, ensuring compliance with stock exchange notification requirements for both BSE and NSE listings.

Shilpa Medicare and its partner Mabtree Biologics have achieved a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) granting orphan drug designation for their new biologic treatment targeting rare blood cancers.

Orphan Drug Designation Benefits

The FDA orphan drug designation provides several strategic advantages for the development and commercialization of treatments for rare diseases. This status offers regulatory benefits that can accelerate the drug development process and provide market incentives for companies developing treatments for conditions affecting fewer than 200,000 patients in the United States.

Rare Blood Cancer Treatment Focus

The biologic treatment specifically targets rare blood cancers, addressing a significant unmet medical need in hematological malignancies. Rare blood cancers often have limited treatment options, making the development of new therapeutic approaches crucial for patient outcomes.

Clinical Development Support

The orphan drug designation provides enhanced clinical development support from the FDA, including:

• Priority review processes
• Increased regulatory guidance
• Specialized consultation opportunities
• Streamlined approval pathways

This regulatory framework is designed to encourage pharmaceutical companies to invest in treatments for rare diseases that might otherwise be commercially unviable due to small patient populations.

Strategic Partnership

The collaboration between Shilpa Medicare and Mabtree Biologics demonstrates a focused approach to developing specialized treatments for rare diseases. This partnership combines expertise in pharmaceutical development with regulatory strategy to advance innovative biologic treatments through the complex approval process.

The orphan drug designation represents a crucial step in bringing this rare blood cancer treatment closer to patients who have limited therapeutic options, while providing the companies with regulatory advantages that support continued investment in rare disease research and development.